← All trials
NCT05244954
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2022
- Primary completion
- Aug 26, 2022
- Completion date
- Aug 26, 2022
- First posted
- Feb 17, 2022
- Last posted
- Nov 15, 2022
- Enrollment
- 746
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MarylandLead sponsor
- University of MarylandOverall official - principal investigator
- University of MarylandReponsible party - principal investigator
- Doris Duke Charitable FoundationCollaborator
- Kamuzu University of Health SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.